Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dihydrouridine synthase 3 like (DUS3L)
- Target
- DUS3L
- Molecular classification
- Enzyme, RNA modification enzyme, Dihydrouridine synthase family (Dus family, Dus3 subfamily)
01
Overview
Dihydrouridine synthase 3 like (DUS3L) is an enzyme that catalyzes the synthesis of dihydrouridine, a modified nucleoside, in tRNAs (especially at position 47 in the D-loop of most cytoplasmic tRNAs) and in some mRNAs and long noncoding RNAs. This modification regulates RNA structure, function, and translation efficiency. DUS3L belongs to a conserved family of RNA modification enzymes and is essential for optimal cellular protein synthesis. Knockout or loss of DUS3L impairs translation and reduces cellular proliferation. DUS3L is linked to certain cancers and congenital disorders, and may represent a potential—but as yet unvalidated—therapeutic target in oncology and RNA biology[1][2][3].
- Other names
- tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-likeDUS3FLJ13896mRNA-dihydrouridine synthase DUS3LtRNA-dihydrouridine synthase 3-like
02
Mechanism of action
Enzymatic reduction of uridine to dihydrouridine in tRNA/mRNA, dependent on FMN and NAD(P)H cofactors[1][3]
03
Biological functions
Regulation of translationtRNA dihydrouridine synthesispost-transcriptional RNA modification
04
Disease associations
Cancer (including association with adenosquamous gallbladder carcinoma)congenital myopathy 12impairment can affect proliferation
05
Safety considerations
No major clinical safety concerns described in the literature; loss-of-function impairs translation and proliferation, which could represent challenges for therapeutic targeting[2]
06
Interacting drugs
No known small molecule drugs or inhibitors are clinically established; chemical probes or experimental inhibitors may exist in the research context[2]
07
Biomarkers
No established clinical biomarkers, but loss of DUS3L activity results in reduced cellular translation and proliferation, which could have experimental biomarker relevance[2]
Beyond the preview
Go deeper on Dihydrouridine synthase 3 like (DUS3L).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dihydrouridine synthase 3 like (DUS3L).